Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

NCT05957510 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: Serplulimab
DRUG: SOC

Sponsor

Guangdong Association of Clinical Trials

Collaborators

[object Object]